Tradestie Institutional Equity Comparison Engine · Market Close Feb 25, 2026

CLSD vs CASI: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

CASI Wins Head-to-Head Institutional Verdict (3–1 across 6 Pillars · 5–2 Matrix Metrics)

CASI Overall Winner 6-Pillar Tally: CLSD 1 – 3 CASI (2 Tie) Matrix Metrics: CLSD 2 – 5 CASI

As of Feb 25, 2026, CASI Pharmaceuticals, Inc. (CASI) is the stronger overall head-to-head candidate over Clearside Biomedical, Inc. (CLSD) in the Tradestie Institutional Equity Comparison Engine, winning 5–2 core matrix metrics and 3–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). CLSD carries a Unified Composite Score of 43.3/100 (HOLD) at $0.41 (N/M Forward P/E, -3502.5% operating margin), whereas CASI carries 44.7/100 (HOLD) at $0.21 (N/M Forward P/E, -333.1% operating margin).

  • Technical & Structure Timing Caution: CLSD trades in a Neutral technical trend (UNCLASSIFIED options phase, RSI 17.4); meanwhile CASI is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 18.4). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About CLSD vs CASI
CLSD NASDAQ
Clearside Biomedical, Inc. Common Stock
Pharmaceutical Preparations
$0.41
-26.96% 1D
Market Cap $2.9M
TTM Revenue $3.3M
Forward P/E N/M
Beta / 30D Vol 2.24β · 269% Vol
Unified Composite Score
43.3 / 100 HOLD
Tech 40.0 Fund 43.0 Flow 50.0 Mom 40.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 17
RSI-14: 17.4 · SMA20: $2.98 · SMA50: $3.60
CASI NASDAQ Head-to-Head Winner
CASI Pharmaceuticals, Inc. Ordinary Shares
Pharmaceutical Preparations
$0.21
-74.06% 1D
Market Cap $12.4M
TTM Revenue $27M
Forward P/E N/M
Beta / 30D Vol 0.95β · 240% Vol
Unified Composite Score
44.7 / 100 HOLD
Tech 40.0 Fund 44.0 Flow 50.0 Mom 44.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -9.5%), weak momentum, RSI 18
RSI-14: 18.4 · SMA20: $0.84 · SMA50: $0.88

6-Pillar Scorecard Institutional Category Breakdown (CLSD 1 – 3 CASI)

Columns: Metric · CLSD · CASI
1. Valuation Multiples CASI
Forward P/E N/M N/M
Trailing P/E N/M N/M
PEG Ratio N/M N/M
EV / Revenue 0.9x 0.5x
2. Growth & Scale CASI
Revenue Growth (YoY) -80.6% -60.5%
Earnings Growth (YoY) +0.0% +0.0%
TTM Revenue (USD) $3.3M $27M
Market Cap $2.9M $12.4M
3. Profitability & Quality CASI
Gross Margin 88.1% 35.8%
Operating Margin -3502.5% -333.1%
Net Profit Margin 0.0% -184.0%
Return on Equity (ROE) -1310.0% -1094.5%
4. Balance Sheet & Cash Flow CLSD
Cash Generation (TTM) -$23M EBITDA -$42M EBITDA
Cash Flow Margin N/A N/A
Net Cash / Leverage -1310.0% ROE -1094.5% ROE
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning Tie
Options Structure Phase UNCLASSIFIED UNCLASSIFIED
Current IV / %ile N/A (N/A) N/A (N/A)
Put/Call OI Skew N/A N/A
OBV Trend / Tech Phase NEUTRAL · Neutral NEUTRAL · Markdown
6. R&D & Supply-Chain Moat Tie
OpEx & R&D Intensity N/A N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Pharmaceutical Preparations Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: CLSD (2) vs CASI (5)
Institutional Metric CLSD CASI Criterion Row Edge
Market Capitalization
Scale
$2.9M $12.4M Larger Scale Tie
Trailing P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Forward P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Revenue Growth (YoY)
Growth
-80.6% -60.5% Higher Growth CASI
Operating Margin (TTM)
Profitability
-3502.5% -333.1% Higher Margin CASI
Net Profit Margin
Profitability
0.0% -184.0% Higher Margin CLSD
Return on Equity (ROE)
Capital Efficiency
-1310.0% -1094.5% Higher ROE CASI
52-Week Range Position
Momentum
1% ($0–$17) 0% ($0–$3) Stronger Trend CLSD
Beta / 30D Volatility
Risk Regime
2.24β · 269% Vol 0.95β · 240% Vol Lower Realized Risk CASI
Unified Institutional Score
Composite Signal
43.3 / 100 (HOLD) 44.7 / 100 (HOLD) Higher Composite CASI
Trailing 12M Revenue (USD)
Operating Scale
$3.3M $27M FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
88.1% 35.8% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · 0.9x EV/Rev N/M PEG · 0.5x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$23M EBITDA (-1310.0% ROE) -$42M EBITDA (-1094.5% ROE) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon CASI +60.69 pp
CLSD: -88.86% · CASI: -28.17%
3M Horizon CLSD +67.4 pp
CLSD: +11.56% · CASI: -55.84%
6M Horizon CASI +0.09 pp
CLSD: -46.12% · CASI: -46.03%
1Y Horizon CASI +39.04 pp
CLSD: -96.89% · CASI: -57.85%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on CLSD vs CASI. Trailing 12-month operating profitability (CLSD -3502.5% vs CASI -333.1%) and valuation multiples (CLSD N/M vs CASI N/M Forward P/E) are benchmarked directly in Pillar 4 below.

CLSD ADR TTM Benchmark FX-Normalized USD
TTM Revenue$3.3M
Gross Margin88.1%
Op. Margin-3502.5%
ROE / Fwd P/E-1310.0% · N/M
CASI ADR TTM Benchmark FX-Normalized USD
TTM Revenue$27M
Gross Margin35.8%
Op. Margin-333.1%
ROE / Fwd P/E-1094.5% · N/M

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
CLSD UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact CLSD Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
CASI UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact CASI Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
CLSD Moat Profile Cyclical / Execution-Driven Positioning
Pharmaceutical Preparations Operator
Competes within the Pharmaceutical Preparations value chain with $2.9M market capitalization and -3502.5% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
CASI Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $12.4M market capitalization and -333.1% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ CLSD vs CASI Key Questions & Quantitative Answers

As of Feb 25, 2026, CASI Pharmaceuticals, Inc. (CASI) is the stronger overall head-to-head candidate over Clearside Biomedical, Inc. (CLSD) in the Tradestie Institutional Equity Comparison Engine, winning 5–2 core matrix metrics and 3–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). CLSD carries a Unified Composite Score of 43.3/100 (HOLD) at $0.41 (N/M Forward P/E, -3502.5% operating margin), whereas CASI carries 44.7/100 (HOLD) at $0.21 (N/M Forward P/E, -333.1% operating margin). Technical & Structure Timing Caution: CLSD trades in a Neutral technical trend (UNCLASSIFIED options phase, RSI 17.4); meanwhile CASI is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 18.4). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

CASI leads the Growth & Scale pillar: CLSD posts -80.6% YoY revenue growth and +0.0% YoY earnings growth on $3.3M TTM revenue (88.1% gross margin, -3502.5% operating margin), compared with CASI at -60.5% YoY revenue growth and +0.0% YoY earnings growth on $27M TTM revenue (35.8% gross margin, -333.1% operating margin). On trailing 12-month operating scale, CLSD generates $3.3M in USD-normalized revenue versus $27M for CASI. In operating R&D and SG&A reinvestment, CLSD deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for CASI.

CASI screens cheaper on headline valuation multiples. CLSD trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 0.9x EV/Revenue (unreported EBITDA margin), whereas CASI trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 0.5x EV/Revenue (unreported EBITDA margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against CLSD (-1310.0% ROE) versus CASI (-1094.5% ROE) capital efficiency.

In options market volatility and institutional positioning, CLSD carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (2.24β · 269% Vol realized risk). By comparison, CASI carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.95β · 240% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Feb 25, 2026. For educational research only; not investment advice.